The stock of Tandem Diabetes Care Inc (NASDAQ:TNDM) reached all time low today, Oct, 28 and still has $5.31 target or 13.00% below today’s $6.10 share price. This indicates more downside for the $180.72M company. This technical setup was reported by Barchart.com. If the $5.31 PT is reached, the company will be worth $23.49 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 68,465 shares traded hands. Tandem Diabetes Care Inc (NASDAQ:TNDM) has declined 24.91% since March 28, 2016 and is downtrending. It has underperformed by 29.62% the S&P500.
Analysts await Tandem Diabetes Care Inc (NASDAQ:TNDM) to report earnings on November, 3. They expect $-0.58 earnings per share, up 10.77% or $0.07 from last year’s $-0.65 per share. After $-0.60 actual earnings per share reported by Tandem Diabetes Care Inc for the previous quarter, Wall Street now forecasts -3.33% EPS growth.
Tandem Diabetes Care Inc (NASDAQ:TNDM) Ratings Coverage
Out of 2 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 0 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 0 are positive. Tandem Diabetes Care has been the topic of 10 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Bank of America on Thursday, January 14. The rating was downgraded by Zacks to “Buy” on Friday, August 28. The stock of Tandem Diabetes Care Inc (NASDAQ:TNDM) has “Hold” rating given on Friday, September 4 by Zacks. The firm earned “Sell” rating on Wednesday, August 5 by Zacks. The rating was downgraded by Bank of America to “Underperform” on Thursday, March 24. The firm earned “Buy” rating on Thursday, August 20 by Zacks. The firm has “Buy” rating given on Monday, August 10 by Deutsche Bank. The stock of Tandem Diabetes Care Inc (NASDAQ:TNDM) has “Hold” rating given on Saturday, August 22 by Zacks.
According to Zacks Investment Research, “Tandem Diabetes Care, Inc. is a medical device company. The Company designs, develops, and commercializes products for people with insulin-dependent diabetes. Its products include t:slim Insulin Delivery System. Tandem Diabetes Care, Inc. is headquartered in San Diego, California.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.26, from 1.28 in 2016Q1. The ratio fall, as 18 funds sold all Tandem Diabetes Care Inc shares owned while 24 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 17.85 million shares or 6.33% less from 19.06 million shares in 2016Q1.
Teachers Advsrs, a New York-based fund reported 28,241 shares. Stonebridge Management accumulated 10,405 shares or 0.04% of the stock. Hood River Capital Management Ltd Liability has invested 0.53% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM). Eventide Asset Mgmt Limited Liability Corp holds 275,000 shares or 0.13% of its portfolio. Nationwide Fund holds 0% or 12,415 shares in its portfolio. Senzar Asset Mgmt Ltd holds 615,311 shares or 0% of its portfolio. Deutsche Bank Ag accumulated 60,941 shares or 0% of the stock. Envestnet Asset Mgmt holds 0% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM) for 1,649 shares. Jennison Assocs Limited Liability Corp accumulated 37,033 shares or 0% of the stock. Cubist Systematic Strategies Limited Liability Company accumulated 3,834 shares or 0% of the stock. Rock Springs Capital Management L P has 595,000 shares for 0.33% of their US portfolio. Bogle L P De holds 0.06% or 122,811 shares in its portfolio. Bluestein R H & Com holds 0.01% or 10,625 shares in its portfolio. Blackrock owns 1,269 shares or 0% of their US portfolio. Tpg Group Incorporated (Sbs) Advsrs has invested 0.21% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM).
Insider Transactions: Since May 2, 2016, the stock had 0 insider purchases, and 1 sale for $21,213 net activity. The insider Sheridan John F sold 2,000 shares worth $21,213.
More notable recent Tandem Diabetes Care Inc (NASDAQ:TNDM) news were published by: Businesswire.com which released: “Tandem Diabetes Care Now Shipping Next-Generation t:slim X2 Insulin Pump” on October 24, 2016, also Businesswire.com with their article: “Tandem Diabetes Care Schedules Third Quarter 2016 Earnings Press Release and …” published on October 19, 2016, Fool.com published: “Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today” on May 03, 2016. More interesting news about Tandem Diabetes Care Inc (NASDAQ:TNDM) were released by: Prnewswire.com and their article: “Tandem Diabetes Care Announces FDA Approval of t:slim G4 Insulin Pump with CGM …” published on September 09, 2015 as well as Businesswire.com‘s news article titled: “Tandem Diabetes Care Now Taking Orders for Next-Generation t:slim X2 Insulin Pump” with publication date: October 04, 2016.
TNDM Company Profile
Tandem Diabetes Care, Inc., incorporated on January 7, 2008, is a medical device company. The Firm is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Firm makes and sells over three insulin pump products in the United States that are designed to address insulin-dependent diabetes market, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). The Company’s technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump’s cartridge rather than relying on a syringe and plunger mechanism. The Firm also features a software, which is a vivid color touch screen and a micro- universal serial bus (USB) connection that supports both a rechargeable battery and uploads to t:connect Diabetes Management Application (t:connect), its custom cloud data management application that provides display therapy management data from the pump and supported blood glucose meters.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.